Endpoints News 生物医药· Elizabeth Cairns·· 2026-09-30AI 评分58
EASD26:礼来 amylin-Zepbound 联用方案在肥胖合并糖尿病人群中展示最高减重效果
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
AI 导读
在 EASD26 会议上,礼来展示的 amylin-Zepbound 联用方案在肥胖合并糖尿病受试者中取得了迄今最高的减重效果。文章指出该联用方案的表现优于 Wegovy、Zepbound、CagriSema 及 retatrutide。因正文存在付费墙截断,当前材料仅披露了会议名称与初步对比结果。
正文
MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP.
Data revealed Wednesday show that Lilly’s …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news